Brokerages Set Caladrius Biosciences Inc. (CLBS) Price Target at $6.63
Shares of Caladrius Biosciences Inc. (NASDAQ:CLBS) have earned an average recommendation of “Buy” from the six research firms that are presently covering the stock. One analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $6.63.
A number of brokerages have recently commented on CLBS. Zacks Investment Research cut shares of Caladrius Biosciences from a “buy” rating to a “hold” rating in a research note on Friday, July 29th. Chardan Capital reaffirmed a “buy” rating and set a $6.50 price objective on shares of Caladrius Biosciences in a research note on Wednesday, November 9th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Caladrius Biosciences in a research note on Wednesday, August 10th.
Caladrius Biosciences (NASDAQ:CLBS) opened at 4.05 on Wednesday. The company’s 50 day moving average is $4.05 and its 200 day moving average is $5.05. Caladrius Biosciences has a 12-month low of $3.26 and a 12-month high of $13.50.
Caladrius Biosciences (NASDAQ:CLBS) last issued its quarterly earnings data on Monday, November 7th. The company reported ($1.09) EPS for the quarter, topping analysts’ consensus estimates of ($1.55) by $0.46. Caladrius Biosciences had a negative net margin of 183.36% and a negative return on equity of 270.38%. Analysts predict that Caladrius Biosciences will post ($5.04) earnings per share for the current year.
A number of large investors have recently added to or reduced their stakes in CLBS. Vanguard Group Inc. boosted its stake in Caladrius Biosciences by 1.6% in the second quarter. Vanguard Group Inc. now owns 1,325,847 shares of the company’s stock worth $783,000 after buying an additional 20,424 shares in the last quarter. Hollencrest Securities LLC bought a new stake in Caladrius Biosciences during the third quarter worth about $570,000. Eagle Global Advisors LLC bought a new stake in Caladrius Biosciences during the third quarter worth about $127,000. Finally, Knoll Capital Management LP bought a new stake in Caladrius Biosciences during the third quarter worth about $266,000. 49.79% of the stock is currently owned by hedge funds and other institutional investors.
About Caladrius Biosciences
Caladrius Biosciences, Inc, formerly NeoStem, Inc, through its subsidiary, PCT, LLC, a Caladrius Company (PCT), provides development and manufacturing services to the cell therapy industry (which includes cell-based gene therapy). PCT specializes in cell and cell-based gene therapies. PCT offers development and manufacturing capabilities, quality systems, cell and tissue processing, logistics, storage and distribution and engineering solutions to clients with therapeutic candidates at all stages of development.
Receive News & Stock Ratings for Caladrius Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences Inc. and related stocks with our FREE daily email newsletter.